Parker RJ - Search Results

1

Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.

Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E. Parker RJ, et al. Carcinogenesis. 1991 Jul;12(7):1253-8. doi: 10.1093/carcin/12.7.1253. Carcinogenesis. 1991. PMID: 2070490 Clinical Trial.

2

Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.

Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM, Reed E. Dabholkar M, et al. Among authors: parker rj. Environ Health Perspect. 1992 Nov;98:53-9. doi: 10.1289/ehp.929853. Environ Health Perspect. 1992. PMID: 1486863 Free PMC article.

3

Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts.

Gill I, Muggia FM, Terheggen PM, Michael C, Parker RJ, Kortes V, Grunberg S, Christian MC, Reed E, den Engelse L. Gill I, et al. Among authors: parker rj. Ann Oncol. 1991 Feb;2(2):115-21. doi: 10.1093/oxfordjournals.annonc.a057872. Ann Oncol. 1991. PMID: 2054312 Free article. Clinical Trial.

4

Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance.

Lee KB, Parker RJ, Reed E. Lee KB, et al. Among authors: parker rj. Cancer Lett. 1995 Jan 6;88(1):57-66. doi: 10.1016/0304-3835(94)03626-t. Cancer Lett. 1995. PMID: 7850774

5

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Lee KB, et al. Among authors: parker rj. Carcinogenesis. 1993 Oct;14(10):2177-80. doi: 10.1093/carcin/14.10.2177. Carcinogenesis. 1993. PMID: 8222071

6

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM. Reed E, et al. Among authors: parker rj. Cancer Res. 1993 Aug 15;53(16):3694-9. Cancer Res. 1993. PMID: 8339278 Clinical Trial.

7

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E. Parker RJ, et al. Cancer Res. 1993 Jan 15;53(2):242-7. Cancer Res. 1993. PMID: 8417816

8

Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy.

Parker R, Dimery I, Dabholkar M, Vionnet J, Reed E. Parker R, et al. Int J Oncol. 1993 Aug;3(2):331-5. doi: 10.3892/ijo.3.2.331. Int J Oncol. 1993. PMID: 21573369

9

Peripheral blood leukocytes as a surrogate marker for cisplatin drug resistance: studies of adduct levels and the repair gene ERCC1.

Parker RJ, Poirier MC, Bostick-Bruton F, Vionnet J, Bohr VA, Reed E. Parker RJ, et al. Basic Life Sci. 1990;53:251-61. doi: 10.1007/978-1-4613-0637-5_20. Basic Life Sci. 1990. PMID: 1704215 No abstract available.

10

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Parker RJ, et al. J Clin Invest. 1991 Mar;87(3):772-7. doi: 10.1172/JCI115080. J Clin Invest. 1991. PMID: 1999494 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters